The text starts here.

Non-Consolidated Semiannual Financial Report for fiscal 1997

MAJOR R&D PIPELINE CANDIDATES (INTERNATIONAL)

1. APPROVED (INTERNATIONAL)

Brand (Code)

Description

Form Origin
ARICEPT
(E2020)
For the treatment of mild to moderate dementia of the Alzheimer's type Tab. In house
Note: In Eisai's territories, ARICEPT received marketing approval in Germany and France in August 1997, and Eisai began marketing ARICEPT in Germany in October 1997. In France, marketing preparations are in process. Eisai began marketing ARICEPT in the US in January 1997 and in the UK in April 1997. In other licensed-out territories, as of the end of October 1997, ARICEPT was marketed in Canada, Switzerland, Sweden, Denmark, Finland, and received marketing approval in Austria, Ireland, Italy, Greece, Spain, Belgium, Luxembourg and Mexico.

2. FILED FOR APPROVAL (INTERNATIONAL)

Code

Area Filed

Target Disease/Classification

Form Origin
E2020 Asia* Jun-97 Alzheimer's Disease/Reversible Acetylcholinesterase Inhibitor Tab. In-house
E3810 UK Jan-97 Peptic Ulcer/Proton Pump Inhibitor Tab. In-house
*: As of the end of October 1997, E2020 was filed for approval in China, Hong Kong, Korea, Malaysia, the Philippines, Thailand and Singapore.

3. INTERNATIONAL DEVELOPMENT

Code

Area Stage Filing
(Est)

Target Disease / Classification

Form Origin
E3810 USA Phase III 1998 Peptic Ulcer / Proton Pump Inhibitor Tab. In-house
E4031 Europe Phase II - Arrhythmia / Class III Anti-arrhythmic Agent Tab./Inj. In-house
E5510 Europe Phase II - Thrombosis / Anti-thrombotic, Anti-platelet Tab. In-house
E5531 USA Phase II - Septic Shock / Endotoxin Antagonist Inj. In-house